Abstract

Nocturnal hypoglycemia (NH) is one of the most challenging events for multiple dose insulin therapy (MDI) in people with type 1 diabetes (T1D). The goal of this study is to design a method to reduce the incidence of NH in people with T1D under MDI therapy, providing a decision-support system and improving confidence toward self-management of the disease considering the dataset used by Bertachi et al. Different machine learning (ML) algorithms, data sources, optimization metrics and mitigation measures to predict and avoid NH events have been studied. In addition, we have designed population and personalized models and studied the generalizability of the models and the influence of physical activity (PA) on them. Obtaining 30 g of rescue carbohydrates (CHO) is the optimal value for preventing NH, so it can be asserted that this is the value with which the time under 70 mg/dL decreases the most, with almost a 35% reduction, while increasing the time in the target range by 1.3%. This study supports the feasibility of using ML techniques to address the prediction of NH in patients with T1D under MDI therapy, using continuous glucose monitoring (CGM) and a PA tracker. The results obtained prove that BG predictions can not only be critical in achieving safer diabetes management, but also assist physicians and patients to make better and safer decisions regarding insulin therapy and their day-to-day lives.

Highlights

  • Type 1 diabetes (T1D) is a chronic condition resulting from the autoimmune destruction of insulin-producing β cells in the pancreas [1,2]

  • While these treatments allow patients to reduce the amount of blood glucose (BG), avoiding hyperglycemia [3,4,5] and reducing complications [1,5], they are burdened by the common side effect of over-lowering glucose which can drive the patient into hypoglycemia

  • The strongest variations in BG signals occur after meals and during the night [4,9,10], the latter variations being the main causes of postprandial hypoglycemia or nocturnal hypoglycemia (NH) [11,12]

Read more

Summary

Introduction

Type 1 diabetes (T1D) is a chronic condition resulting from the autoimmune destruction of insulin-producing β cells in the pancreas [1,2]. People suffering from this condition are treated with lifelong intensive insulin therapies. Consequences of suffering an NH may include confusion, sweating, seizures, and even death [6,13]. These adverse events reduce health-related quality of life and work performance. NHs may cause poor sleep and so reduce the quality of life of T1D patients [15]

Objectives
Methods
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call